1. Home >
  2. Investors >
  3. Growth Capital Firm >
  4. Netherlands >
  5. EQT Life Sciences

EQT Life Sciences Mergers and Acquisitions Summary

Growth Capital Firm Profile

In the last 3 years, EQT Life Sciences has invested in 3 companies.

EQT Life Sciences’ most common sectors for investment arelife science (64%) and medical products (30%) . The Firm’s most common investment types include venture (83%) and growth capital (11%). In total, EQT Life Sciences has invested in 7 US states and 10 different countries.

In the last 3 years, EQT Life Sciences has exited 5 companies. The Firm’s most common exit type is trade sale (86%). EQT Life Sciences’ largest (disclosed) exit occurred in 2024 when it sold Amolyt Pharma SAS for $1.1B.

Sign-up to view EQT Life Sciences’ full profile and discover more large growth capital firm investors just like it.

M&A Summary

  • M&A Total Activity54
    • M&A Buy Activity47
    • M&A Sell Activity7
  • Total Sectors Invested 5
  • Total Countries Invested 10
  • M&A Buy/Sell Connections 13

EQT Life Sciences

EQT Life Sciences

Johannes Vermeerplein 9,
Amsterdam, 1071 DV
Netherlands
+31 (0) 20 664 55 00
eqtgroup.com/private-capital/eqt-life-sciences

EQT Life Sciences (formerly Life Science Partners) is a private investment firm focused on growth and venture capital financing for life sciences and healthcare companies. The Firm targets early to mid‑stage companies in sectors such as therapeutics, medical devices, diagnostics, healthtech, and biotech. EQT Life Sciences was formed in 1986 and is headquartered in Amsterdam, the Netherlands.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products

Target Transaction Types: Growth Capital, Stake Purchase, Venture

Geographic Preferences: East US, Midwest US, South US, West US, United Kingdom, Western Europe, Eastern Europe, Nordic

Transaction Criteria Min Max
Target Revenue - -
Target EBITDA - -
Investment Size - -
Enterprise Value - -

M&A Summary

Buy vs Sell

Year ≤ '20 '21 '22 '23 '24 '25 T
Buy (3.0/yr) # 32 12 2 - 1 - 47
Sell (1.2/yr) # 1 1 - 1 4 - 7
vol $2.1B $2.1B
  54

Most Recent M&A

Company Date Value Type
Endotronix, Inc. 2024-08-20 - Trade Sale
Lisle, Illinois · www.endotronix.com
Lumeon, Inc. 2024-08-08 - Trade Sale
Boston, Massachusetts · www.lumeon.com
Asceneuron SA 2024-07-16 - Growth Capital
Lausanne, Switzerland · www.asceneuron.com
Cardior Pharmaceuticals GmbH 2024-03-25 1.0B USD Trade Sale
Hannover, Germany · www.cardior.de
Amolyt Pharma SAS 2024-03-14 1.1B USD Trade Sale
Ecully, France · www.amolytpharma.com
Atlantic Therapeutics Group Ltd. 2023-09-06 - Trade Sale
Galway, Ireland · ie.myinnovo.com
Perfuze Ltd. 2022-02-09 - Venture
Galway, Ireland · www.perfuze.com
Nobi BV 2022-01-27 - Growth Capital
Antwerp, Belgium · www.nobi.life
AviadoBio Ltd. 2021-12-08 - Venture
London, United Kingdom · www.aviadobio.com
HotSpot Therapeutics, Inc. 2021-11-30 - Venture
Boston, Massachusetts · www.www.hotspotthera.com
View All >>

M&A by Sector

Sector Current # Value All-time # Value
Life Science 26 (67%) - 30 (64%) -
Medical Products 11 (28%) - 14 (30%) -
Healthcare Services 1 (3%) - 1 (2%) -
Information Technology - - 1 (2%) -
Leisure 1 (3%) - 1 (2%) -
Total 39 - 47 -

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 8 (21%) - 11 (23%) -
  Massachusetts 2 (5%) - 3 (6%) -
  California 2 (5%) - 3 (6%) -
  Washington 1 (3%) - 1 (2%) -
  Rhode Island 1 (3%) - 1 (2%) -
  Pennsylvania 1 (3%) - 1 (2%) -
  North Carolina 1 (3%) - 1 (2%) -
  Illinois - - 1 (2%) -
Netherlands 8 (21%) - 10 (21%) -
Belgium 5 (13%) - 5 (11%) -
Ireland 4 (10%) - 5 (11%) -
France 3 (8%) - 4 (9%) -
Germany 3 (8%) - 4 (9%) -
Switzerland 3 (8%) - 3 (6%) -
United Kingdom 2 (5%) - 2 (4%) -
Denmark 2 (5%) - 2 (4%) -
Sweden 1 (3%) - 1 (2%) -
Total 39 - 47 -

Acquisitions by Deal Type

Type Current # Value All-time # Value
Venture 32 (82%) - 39 (83%) -
Growth Capital 5 (13%) - 5 (11%) -
Stake Purchase 1 (3%) - 2 (4%) -
Buyout (LBO, MBO, MBI) 1 (3%) - 1 (2%) -
Total 39 - 47 -

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 4 (57%) 2.1B (100%)
Trade Sale 2 (29%) -
IPO 1 (14%) -
Total 7 $2.1B

Deal Values

sell # Total
> $1B 2 $2.1B
TOTAL $2.1B
Largest Amolyt Pharma SAS
$1.1B (2024-03-14)

M&A Connections

Deals
Exited to
Strategic(s)
86%
6 (86%)

Investor Summary

Investor Type

Growth Capital Firm

Size

Large

PE Assets

3.5B EUR

Established

1987

Specialist/Generalist

Specialist

Subsidiary of

EQT

FAQ

When was EQT Life Sciences founded?

EQT Life Sciences was founded in 1987.

What type of investor is EQT Life Sciences?

EQT Life Sciences is a growth capital firm.

Where is EQT Life Sciences headquartered?

EQT Life Sciences is headquartered in Amsterdam, Netherlands.

How much capital does EQT Life Sciences have under management?

EQT Life Sciences has 3.5B EUR under management.

Try Mergr Free — See This and 215,174+
Other Company and Investor Profiles Today

Try free. Full access. Cancel anytime.

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
Try Free

What's Mergr?

Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.

We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.

With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.7K Private Equity Firms
  • 209K M&A Transactions
  • 210K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.7K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

What next?

Try Free

Full access to Mergr's investor, acquirer, and transaction data starts here.

Mergr

Solution for

Product

Company

Legal